RT Journal Article
SR Electronic
T1 Genome-wide association analysis and Mendelian randomization proteomics identify drug targets for heart failure
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.14.22273877
DO 10.1101/2022.04.14.22273877
A1 Rasooly, Danielle
A1 Peloso, Gina M
A1 Pereira, Alexandre C
A1 Dashti, Hesam
A1 Giambartolomei, Claudia
A1 Wheeler, Eleanor
A1 Aung, Nay
A1 Ferolito, Brian R
A1 Pietzner, Maik
A1 Farber-Eger, Eric H
A1 Wells, Quinn Stanton
A1 Kosik, Nicole M
A1 Gaziano, Liam
A1 Posner, Daniel C
A1 Bento, A Patrícia
A1 Hui, Qin
A1 Liu, Chang
A1 Aragam, Krishna
A1 Wang, Zeyuan
A1 Charest, Brian
A1 Huffman, Jennifer E
A1 Wilson, Peter W.F.
A1 Phillips, Lawrence S
A1 Whittaker, John
A1 Munroe, Patricia B
A1 Petersen, Steffen E
A1 Cho, Kelly
A1 Leach, Andrew R
A1 Magariños, María Paula
A1 Gaziano, John Michael
A1 VA Million Veteran Program
A1 Langenberg, Claudia
A1 Sun, Yan V
A1 Joseph, Jacob
A1 Casas, Juan P
YR 2023
UL http://medrxiv.org/content/early/2023/05/26/2022.04.14.22273877.abstract
AB We conduct a large-scale meta-analysis of heart failure genome-wide association studies (GWAS) consisting of over 90,000 heart failure cases and more than 1 million control individuals of European ancestry to uncover novel genetic determinants for heart failure. Using the GWAS results and blood protein quantitative loci, we perform Mendelian randomization and colocalization analyses on human proteins to provide putative causal evidence for the role of druggable proteins in the genesis of heart failure. We identify 39 genome-wide significant heart failure risk variants, of which 18 are previously unreported. Using a combination of Mendelian randomization proteomics and genetic cis-only colocalization analyses, we identify 10 additional putatively causal genes for heart failure. Findings from GWAS and Mendelian randomization-proteomics identify seven (CAMK2D, PRKD1, PRKD3, MAPK3, TNFSF12, APOC3 and NAE1) proteins as potential targets for interventions to be used in primary prevention of heart failure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is supported by funding from the Department of Veterans Affairs Office of Research and Development, Million Veteran Program Grant I01-CX001737 and I01-BX004821. This publication does not represent the views of the Department of Veterans Affairs or the United States Government. We also acknowledge the VA Merit Grant I01-CX001025 (PI: Wilson/Cho).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Veterans Affairs Central Institutional Review Board ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors